| Trial ID: | L4068 |
| Source ID: | NCT00296296
|
| Associated Drug: |
Cyclosporin
|
| Title: |
Immunosuppression Impact on the Metabolic Control of Kidney Transplant With Pre-Existing Type 2 Diabetes (DM)
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT00296296/results
|
| Conditions: |
Kidney Transplant|Diabetes Mellitus, Type 2|Diabetic Nephropathy
|
| Interventions: |
DRUG: Cyclosporin|DRUG: Tacrolimus|BEHAVIORAL: 'Diabetes Education / Management'
|
| Outcome Measures: |
Primary: Freedom From Insulin Therapy Post Transplant, The count of participants with freedom from insulin therapy post transplant is reported., From hospital discharge to 1 year post-transplant|Estimated Glomerular Filtration Rate (eGFR) 1 Year Following Transplantation, Values of ≥60 ml/min/1.73 m\^2 are considered optimal; ≥30-59 ml/min/1.73 m\^2 are indicative of successful graft function; lower values are indicative or graft dysfunction., 1 year post-transplantation | Secondary: Patient Survival at One Year Post Transplantation, Count of participants alive at one year post transplantation, Up to 1 year post-transplantation|Count of Participants With Biopsy Proven Acute Rejection at One Year Post Transplantation, 1 year post-transplantation
|
| Sponsor/Collaborators: |
Sponsor: Stanford University
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
29
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2005-06
|
| Completion Date: |
2014-10
|
| Results First Posted: |
2017-10-06
|
| Last Update Posted: |
2017-10-06
|
| Locations: |
Stanford university Hospital and Clinics, Stanford, California, 94305, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT00296296
|
